Sonelokimab + Placebo

Phase 3Active

0 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hidradenitis Suppurativa

Conditions

Hidradenitis Suppurativa

Trial Timeline

May 15, 2024 → Jun 17, 2026

NCT ID

NCT06411899

About Sonelokimab + Placebo

Sonelokimab + Placebo is a phase 3 stage product being developed by MoonLake Immunotherapeutics for Hidradenitis Suppurativa. The current trial status is active. This product is registered under clinical trial identifier NCT06411899. Target conditions include Hidradenitis Suppurativa.

What happened to similar drugs?

1 of 20 similar drugs in Hidradenitis Suppurativa were approved

Approved (1) Terminated (0) Active (19)

✅Placebo + AdalimumabAbbVieApproved

🔄SonelokimabMoonLake ImmunotherapeuticsPhase 3

🔄Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3

🔄Lutikizumab + PlaceboAbbViePhase 3

🔄Upadacitinib + PlaceboAbbViePhase 3

🔄adalimumab + placeboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06641076	Phase 3	Active	Oct 15, 2024	Feb 4, 2027	Arthritis, Psoriatic
NCT06411899	Phase 3	Active	May 15, 2024	Jun 17, 2026	Hidradenitis Suppurativa
NCT06411379	Phase 3	Active	May 14, 2024	Jun 17, 2026	Hidradenitis Suppurativa

Competing Products

20 competing products in Hidradenitis Suppurativa

See all competitors

Product	Company	Stage	Hype Score
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	41
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	41
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	38
Sonelokimab (M1095) + Adalimumab	MoonLake Immunotherapeutics	Phase 2	29
Eltrekibart + Placebo	Eli Lilly	Phase 2	39
Placebo + LY3041658	Eli Lilly	Phase 2	35
Placebo + Adalimumab	AbbVie	Approved	43
Lutikizumab + Placebo	AbbVie	Phase 3	47
Adalimumab	AbbVie	Pre-clinical	26
Upadacitinib + Placebo	AbbVie	Phase 3	47
adalimumab + placebo	AbbVie	Phase 3	40
Lutikizumab	AbbVie	Phase 2	42
adalimumab	AbbVie	Phase 3	40
Lutikizumab + Placebo	AbbVie	Phase 2	39
Risankizumab + Placebo for risankizumab	AbbVie	Phase 2	35
adalimumab	AbbVie	Phase 3	40
adalimumab + placebo	AbbVie	Phase 3	40
Upadacitinib + Placebo	AbbVie	Phase 2	35
MEDI8968 + Saline	AstraZeneca	Phase 2	27
Anifrolumab	AstraZeneca	Phase 2	39